Viral Infection and Innate Immune Evasion
Viral infections exploit innate immune delays: RNA viruses (influenza, coronaviruses, RSV) evade initial detection by interfering with RIG-I/MDA5 signalling, suppressing IFN-β production and delaying type I interferon response by 6–24 hours. This window allows exponential viral replication. NK cell suppression (via viral MHC-I downregulation interference) and dendritic cell maturation impairment further delay adaptive immunity engagement. Enveloped viruses (herpesviruses, HIV, RSV) rely on surface glycoprotein binding to host receptors (ACE2, CD4, heparan sulphate proteoglycans) for cell entry, making glycoprotein antagonism a therapeutic target.
Spirulina Antiviral Mechanisms
Calcium-Spirulan Sulphated Polysaccharide Entry Inhibition
Calcium-spirulan (Ca-SP), a unique sulphated polysaccharide from Spirulina platensis, competitively binds viral envelope glycoproteins and heparan sulphate proteoglycan (HSPG) co-receptors on host cells. Ca-SP inhibits HSV-1/2, HIV-1, influenza A, measles, and mumps viral entry by 40–70% in cell culture models (IC50 0.4–8 μg/mL). Mechanism: Ca-SP calcium coordination creates a polyanionic surface mimicking host HSPG, binding viral glycoproteins (gB/gC for HSV, gp120 for HIV) and preventing fusion peptide activation. Broad-spectrum entry inhibition occurs without cytotoxicity at active concentrations (selectivity index >50).
Phycocyanin Interferon-β Induction
Spirulina phycocyanin activates TLR3 (dsRNA sensor) and TLR7 (ssRNA sensor) signalling cascades in plasmacytoid dendritic cells and macrophages, driving IRF3/IRF7 nuclear translocation and IFN-β/IFN-α gene transcription (+2–4-fold IFN-β in PBMCs). Type I interferon induces antiviral state in uninfected neighbouring cells: ISG15, Mx1, PKR, and OAS1 expression suppresses viral RNA replication machinery. Phycocyanin also activates STING pathway via cGAS-mediated sensing, contributing to type I IFN production in non-TLR pathways.
NK Cell Priming and Cytotoxicity Enhancement
Spirulina polysaccharides and phycocyanin activate NK cells through NKG2D and NKp46 receptor upregulation (+20–35% surface expression), increasing cytotoxic granule exocytosis (perforin/granzyme B release) against virus-infected target cells by 25–40%. NK cell IFN-γ secretion increases 2–3-fold, contributing to macrophage M1 activation for viral antigen clearance. In vivo influenza models, spirulina-supplemented animals show 30–50% reduction in lung viral titres at 72 hours post-infection, correlating with enhanced NK activity.
RIG-I/MDA5 Pathway Upregulation
Spirulina polyphenols upregulate baseline expression of RIG-I, MDA5, and MAVS (mitochondrial antiviral-signalling protein) in epithelial cells ( +25–40% mRNA at basal state), lowering the threshold for pattern recognition receptor activation upon viral RNA detection. Enhanced MAVS signalling drives earlier NF-κB and IRF3 activation upon infection, closing the innate immune evasion window from 6–24 hours to 2–8 hours. This “primed” antiviral state reduces initial viral replication burden by 30–50% in airway epithelial cells.
Clinical and In Vivo Outcomes
- Influenza viral titres (murine models): −30–50% at 72h post-infection
- IFN-β induction (PBMCs): +2–4-fold over 24–48 hours
- NK cytotoxicity: +25–40% vs. unstimulated baseline
- HSV-1 entry inhibition (Ca-SP): −40–70% (IC50 0.4–8 μg/mL)
- Duration of cold/flu symptoms (human pilot): −1–2 days
- Respiratory illness frequency: −20–35% in 12-week intervention
Dosing and Drug Interactions
Prophylactic antiviral support: 3–5g daily year-round; increase to 5–10g during exposure periods. Acute infection: 5–10g daily; begin at first symptom onset. Antivirals (acyclovir, oseltamivir): Complementary; entry inhibition + intracellular replication targeting are additive. Immunosuppressants: Monitor; NK cell priming may partly overcome immunosuppression. Summary: Ca-SP entry inhibition −40–70%, IFN-β +2–4-fold, NK +25–40%, RIG-I priming −30–50% viral replication; dosing 5–10g daily during illness.